Treatment options in patients with systemic sclerosis-associated interstitial lung disease
Release Date:
Toby Maher discusses the results of the SENSCIS trial, looking at the safety and efficacy of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with mycophenolate.Read the full article:https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30458-6/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Treatment options in patients with systemic sclerosis-associated interstitial lung disease